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ABSTRACT
Background: To date, there are no studies evaluating the use 
of the titanium-nitride-oxide coated stent in patients with 
multivessel coronary artery disease. We have compared the 
performance of the Titan-2® stent to that of the second gen-
eration drug-eluting stents in this scenario. Methods: From 
2011 to 2012, 284 patients were treated with the Titan-2® 
stent, of which 100 (35.2%) had multivessel coronary artery 
disease. This group was compared to 100 patients, of a group 
of 304 (38.9%) patients with multivessel coronary artery dis-
ease treated with second generation drug-eluting stents with 
durable or biodegradable polymers. The primary endpoint was 
the occurrence of major adverse cardiovascular events at 1 
year. Results: Clinical, angiographic and procedure-related 
characteristics of the patients did not show differences between 
groups. Most patients in the Titan-2® group were male (70%), 
mean age was 68.4 ± 12.9 years and 25% were diabetic. 
Stable symptomatic patients were prevalent (68%), 51% had 
three-vessel disease and ventricular function was preserved 
(55.6 ± 12.7%). The incidence of major adverse cardiovascular 
events at 1 year in the Titan-2® group was 21% (vs. 17%; p 
= 0.59), death was observed in 3% (vs. 2%; p > 0.99) of the 
patients, acute myocardial infarction in 5% (vs. 4%; p > 0.99) 
and a new revascularization procedure in 13% (vs. 11%; p = 
0.83). Definitive stent thrombosis was not observed in either 
group. Conclusions: The Titan-2® stent showed similar results 
to those of the second-generation drug-eluting stents, which 
makes it attractive for use in the complex scenario of patients 
with multivessel coronary artery disease. 
DESCRIPTORS: Percutaneous coronary intervention. Stents. 
Coated materials, biocompatible. Titanium.
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RESUMO
Desempenho do Stent Recoberto por Titânio-
Óxido Nítrico em Pacientes com Doença Coronária 
Multiarterial
Introdução: Até o momento, nenhum estudo avaliou o stent 
recoberto por titânio-óxido nítrico em pacientes com doença 
arterial coronariana multiarterial. Comparamos o desempenho 
do stent  Titan-2® ao stents farmacológicos de segunda ge-
ração nesse cenário. Métodos: No período de 2011 a 2012, 
284 pacientes foram tratados com o stent Titan-2®, dos quais 
100 (35,2%) eram portadores de doença arterial coronariana 
multiarterial. Esse grupo foi comparado a 100 pacientes, de 
um grupo de 304 (38,9%), com doença arterial coronariana 
multiarterial, tratados com o stent farmacológico de segunda 
geração com polímeros duráveis ou biodegradáveis. O desfecho 
primário foi a ocorrência de eventos cardíacos adversos maiores 
em 1 ano. Resultados: Características clínicas, angiográficas e 
do procedimento não apresentaram diferenças entre os grupos. 
A maioria dos pacientes do grupo Titan-2® era do sexo mas-
culino (70%), com idade de 68,4 ± 12,9 anos e 25% eram 
diabéticos. Predominaram os quadros clínicos estáveis (68%), 
51% tinham acometimento triarterial e a função ventricular 
estava preservada. A incidência de eventos cardiovasculares 
adversos maiores em 1 ano no grupo Titan-2® foi de 21% (vs. 
17%; p = 0,59), óbito ocorreu em 3% (vs. 2%; p > 0,99) dos 
pacientes, infarto do miocárdio em 5% (vs. 4%; p  >  0,99) 
e nova revascularização miocárdica em 13% (vs. 11%; p = 
0,83). Não foram constatadas tromboses de stent definitivas 
em nenhum grupo. Conclusões: O uso do Titan-2® apresentou 
resultados similares aos do stent farmacológico de segunda 
geração, o que o torna atrativo para ser utilizado no com-
plexo cenário de pacientes portadores de doença arterial 
coronariana multiarterial.
DESCRITORES: Intervenção coronária percutânea. Stents. 
Materiais revestidos biocompatíveis. Titânio.
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C oronary stent implantation has become the stand-ard percutaneous coronary intervention, with a safer approach and better results than those ob-
tained with balloon angioplasty.1,2 However, coronary 
restenosis, although reduced, still remains as a limita-
tion of the procedure, resulting in the need for new 
procedures and increased costs.3 Drug-eluting stents 
(DES) have significantly reduced late luminal loss and 
angiographic restenosis, as well as the need for repeat 
revascularization, when compared to bare metal stents 
(BMS).4 This reduction has been significant in several 
clinical and anatomical scenarios,5-9 especially with 
second-generation stents.8 
The Titan-2® bioactive stent (Hexacath – Paris, 
France) is approved for clinical use in Europe, Asia, 
and North, Central, and South America, including 
Brazil, with more than 5,000 units already used 
worldwide.10,11 This stent consists of stainless steel 
coated with titanium-nitride-oxide, which has shown 
in vitro to reduce platelet aggregation and fibrinogen 
binding when compared to conventional bare metal 
stents. Preliminary data have shown similar safety and 
efficacy profiles of first- and second-generation DES 
in several clinical scenarios.11-18 However, few studies 
have addressed the performance of the Titan-2® in 
the treatment of patients with multivessel coronary 
artery disease (CAD).
This study aimed to evaluate the performance of 
the Titan-2® stent in patients with multivessel CAD and 
compare it to that of second-generation DES. 
METHODS
Patients
From January 2011 to December 2012, 284 pa-
tients were treated at Hospital Beneficência Portuguesa 
de São Paulo with the Titan-2® stent, of whom 100 
(35.2%) had multivessel CAD and were selected for 
this analysis. This study excluded cases whose initial 
clinical presentation was myocardial infarction with 
ST-segment elevation, and those who had lesions > 
50% in the left main coronary artery or when the 
percutaneous coronary intervention was performed 
with saphenous vein grafts. This group was com-
pared to 100 patients from a group of 304 (38.9%) 
patients with multivessel CAD treated with second-
generation DES with durable polymers – Endeavor® 
(Medtronic, Minneapolis, United States) or Xience 
V® (Abbott Vascular, Santa Clara, United States), and 
biodegradable polymers – BioMatrix® (Biosensors 
International, Singapore), in the same period, at the 
present institution.
The study was conducted in agreement with the 
Declaration of Helsinki, and all patients signed an 
informed consent.
The Stents
The Titan-2® balloon-expandable stent combines 
a stainless steel platform (316 L) of thin struts (0.0040 
inch) with open cells and helical connections. It is not 
coated with polymers or antiproliferative drugs, but 
rather with a titanium matrix system bound to nitride 
oxide, applied by vapor deposition on the stent surface. 
Stents that were used as controls included the En-
deavor®, which releases zotarolimus from a biocompatible 
phosphorylcholine polymer applied to a cobalt-chromium 
platform of thin struts; the XienceV®, which releases 
everolimus from a biocompatible fluorinated acrylic 
polymer applied to a platform of cobalt-chromium with 
thin struts; and the BioMatrix®, which releases biolimus 
A9 from a biodegradable polylactic acid polymer applied 
to a stainless steel platform with thin struts.
Procedure
Percutaneous coronary interventions were performed 
according to current guidelines,19,20 and the final strat-
egy for the procedure was left to the discretion of the 
surgeon. 
During the procedure, unfractionated heparin was 
administered at a dose of 70-100  IU/kg, and the use 
of glycoprotein IIb/IIIa inhibitors was at the discretion 
of the surgeon. Pre-dilation was not compulsory, and 
post-dilation of stents was recommended in case of 
residual stenosis > 20% by visual estimation. The ad-
ministration of dual antiplatelet therapy (acetylsalicylic 
acid [loading dose 200 mg/100 mg maintenance] and 
clopidogrel [loading dose 300-600  mg/75  mg mainte-
nance]) should be started at least 24 hours before the 
procedure. In patients with acute coronary syndromes, 
a loading dose of 600  mg of clopidogrel, 60  mg of 
prasugrel, or 180 mg of ticagrelor was recommended. 
After PCI, therapy with aspirin was maintained indefi-
nitely; clopidogrel, prasugrel (10 mg/day), or ticagrelor 
(90  mg/day) were maintained for a period of 1 to 3 
months for the Titan-2® group, and for at least one year 
for the DES group.
Outcomes and clinical follow-up
The primary study endpoint was the occurrence 
of major adverse cardiac events (MACE) during a 
12 month follow-up. MACE was defined as death, 
non-fatal myocardial infarction, and need for repeat 
revascularization. All deaths were considered cardiac 
unless a non-cardiac cause could be clearly established 
by clinical and/or pathological study. The diagnosis of 
myocardial infarction was based on the development of 
new pathological Q waves in more than two contigu-
ous ECG leads and/or elevation of creatine kinase MB 
isoenzyme (CK-MB) greater than three times the upper 
limit of the normal level after the procedure (during the 
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index hospitalization), or twice the upper limit of the 
normal level after discharge. All new revascularizations, 
whether percutaneous or surgical, were considered. 
Definite stent thrombosis was diagnosed according to 
the criteria of the Academic Research Consortium.21
Clinical follow-up was performed at 12 months 
after the procedure, consisting of telephone contact 
performed according to pre-established institutional 
protocol.
Statistical Analysis
Categorical variables were described as percentages 
and compared by the chi-squared or Fisher’s exact test, 
when appropriate. Continuous variables were described 
as means and standard deviations and compared us-
ing Student’s t-test. p-values <  0.05 were considered 
statistically significant.
RESULTS
The clinical, anatomical, and procedural charac-
teristics of the patients are summarized in Table 1, 
demonstrating no statistically significant differences 
between the groups. Most patients from the Titan-2® 
group were males (70%), with a mean age of 68.4 
± 12.9 years, and 25% were diabetics (4.0% used 
insulin). Stable clinical pictures predominated in the 
clinical presentation (68%), 51% had three-vessel CAD, 
and ventricular function was preserved (55.6 ± 12.7%). 
In patients with three-vessel CAD treated with the 
titanium-nitride-oxide stent, 135 lesions were treated. Of 
these, 78% were treated with three or more stents; the 
remaining cases (22%) were treated with two stents. In 
patients with two-vessel CAD, 110 lesions were treated; 
80% of cases were treated with two or more stents 
and only one stent was used in the others. In patients 
with three-vessel CAD treated with drug-eluting stents; 
141 lesions were treated, with three or more stents in 
77% of cases, and with two stents used in the others. 
In patients with two-vessel CAD, 115 lesions were 
treated with two or more stents in 78% of cases, and 
only one stent was used in the others.
The incidence of MACE at 1 year in the Titan-2® 
group was 21% (vs. 17%; p = 0.59) and death occurred 
in 3% (vs. 2%; p > 0.99) of patients, myocardial infarc-
tion in 5% (vs. 4%; p > 0.99), and new revascularization 
procedure in 13% (vs. 11%, p = 0.83), predominantly 
at the expense of a new PCI in more than three-quarters 
of the cases (Table 2). No definite stent thrombosis was 
observed in either group.
DISCUSSION
In this study, it was demonstrated that clinical out-
comes at one year of Titan-2® stent implantation in a 
clinical and anatomical scenario of greater complexity 
(patients with multivessel CAD, of whom approximately 
25% were diabetics with predominantly type B2/C le-
sions according to the classification of the American 
Heart Association/American College of Cardiology) were 
similar to those of the group of patients who received 
second-generation DES implantation with durable or 
biodegradable polymers. 
Modifications of the stent surface and material prop-
erties may have important implications for neointimal 
hyperplasia after stent implantation. Metallic implants 
can induce the exchange of electrons and protons, as 
well as the formation of ion-organic molecular bonds 
in living tissue. The resulting protein activation, cell 
toxicity, and stimulation of platelets, monocytes/macro-
phages, and fibroblasts may contribute to restenosis.22
Both stainless steel and cobalt-chromium have sig-
nificant amounts of nickel, chromium, and molybdenum, 
which can be released from the stent and induce the 
aforementioned tissue reactions. The inflammatory and 
allergic reactions that induce the formation of new tissue 
around metal alloys containing nickel in patients with 
orthopedic and dental implants are well known.23 It is 
reasonable to assume that stents that contain nickel and 
other elements can increase neointimal hyperplasia. 
Several types of stent coating have been used to 
create a biologically inert barrier between the metal-
lic prosthesis surface and the circulating blood, but 
none has reduced rates of restenosis, and others, such 
as gold, increased such rates. An evaluation of five 
different biodegradable polymers and three no biode-
gradable polymers showed inflammatory reactions with 
subsequent coronary neointimal thickening, which was 
not expected based on in vitro tests.24 It is speculated 
that this inflammatory process might contribute to 
coronary restenosis and, eventually, to late thrombosis. 
Thus, it is necessary to improve the characteristics of 
the metallic stents, even as a platform for the release 
of antiproliferative drugs. 
Titanium is the material of choice for biomedical 
implants, especially dental and orthopedic implants, 
because of its superior biocompatibility and resistance 
to corrosion. However, the processing of this metal 
is difficult, and its production costs are prohibitive. 
In contrast, titanium alloys, such as titanium-nitride 
oxide, can be more easily used and applied to stain-
less steel surfaces through physical vapor deposition 
at a reasonable cost. Titanium-nitride-oxide surfaces 
have been experimentally demonstrated to reduce the 
binding of platelets and fibrinogen in comparison to 
stainless steel.25 Moreover, neointimal hyperplasia was 
reduced by 50% in a porcine model, when compared 
to a conventional stainless steel stent.26
When compared to conventional stents, stents coated 
with titanium-nitride-oxide showed to be superior in 
reducing restenosis and major adverse cardiovascular 
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TABLE 1  
Clinical, angiographic, and procedural characteristics
Titanium-nitride-oxide 
coated stent (n = 100/ 
201 vessels/ 245 lesions)
Drug-eluting stent 
(n = 100/201 vessels/  
245 lesions) p-value
Age, years 68.4 ± 12,9 64.5 ± 8.7 0.61
Male gender 70.0 67.0 0.56
Body mass index, Kg/m2 28 ± 4.3 29 ± 4.5 0.11
Current smoking, % 15.0 16 0.93
Arterial hypertension, % 72.0 78.0 0.77
Dyslipidemia, % 75.0 74.0 0.88
Diabetes, % 25.0 26 0.86
Insulin use, % 4.0 5.0 0.88
Previous myocardia linfarction, % 28.0 29.0 0.88
Previous percutaneous coronary intervention, % 2.0 0.0 0.86
Previous coronary artery bypass graft surgery, % 2.0 1.9 0.81
Chronic pulmonary disease, % 10.0 15.0 0.39
Carotid disease, % 10.0 8.0 0.81
Lower-limb peripheral-vascular disease, % 7.0 7.0 > 0.99
Cancer, % 3.0 3.0 > 0.99
Clinical presentation, % 0.17
Stable angina 52.0 53.0
Unstable angina 32.0 35.0
Silent ischemia 16.0 12.0
Left ventricular ejection fraction, % 55.6 ± 12.7 57.5 ± 13.9 0.66
Number of affected vessels, % 0.67
2 49.0 45.0
3 51.0 55.0
Treated vessels,% 0.89
Anterior descending 42.8 46
Right coronary 29.9 33
Circumflex 27.3 21
Type of lesion (American Heart Association/
American College of Cardiology)
0.29
A-B1 29.8 27.0
B2/C 70.2 73.0
Vessel diameter, mm 2.75 ± 0.9 2.85 ± 0.8 0.88
Vessel length 13 ± 3.8 14 ± 3.9 0.89
TABLE 2  
Frequency of major adverse cardiovascular events during a one-year period
Titanium-nitride-oxide coated 
stent (n = 100)
Drug-eluting stent 
(n = 100) p-value
Death, % 3.0 2.0 > 0.99
Myocardial infarction, % 5.0 4.0 > 0.99
Death or myocardial infarction, % 8.0 6.0 0,78
Target lesion revascularization, % 0.83
Coronary artery bypass graft surgery 4.0 3.0
Percutaneous coronary intervention 9.0 8.0
Major adverse cardiovascular events, % 21.0 17.0 0.59
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events.10,25,27 In the case of first- and second-generation 
DES, several studies,11-18 but not all,27,28 demonstrated 
that the Titan-2® showed similar benefits to those of DES 
and did not require prolonged dual antiplatelet therapy 
(> 1 month for stable patients and > 3 months for those 
with acute coronary syndromes), as late thrombosis 
was not observed.17
Study limitations
The results of this study should be interpreted in 
the context of the following limitations: it was a non-
randomized study and, therefore, subject to selection 
biases; the patient population was too small to detect 
differences in clinical events of minor importance; clinical 
information was obtained predominantly by the present 
team or by telephone contact with the assistant phys-
ician, and there was no long-term follow-up (> 1 year).
CONCLUSIONS
This study suggests that the Titan-2® stent has a 
similar safety and efficacy profile to that of second-
generation drug-eluting stents, which makes it attrac-
tive for use in the treatment of the complex scenario 
of patients with multivessel coronary artery disease, 
particularly when long-term dual antiplatelet therapy 
is not intended.
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